Adimmune's COVID-19 vaccine could soon enter clinical trial
ROC Central News Agency
08/17/2020 08:21 PM
Taipei, Aug. 17 (CNA) An experimental COVID-19 vaccine developed by Taiwanese maker Adimmune Corp. has been given conditional approval to enter human trials, according to Taiwan's Food and Drug Administration (FDA) on Monday.
The "AdimrSC-2f vaccine (COVID-19 S-protein)" was found Sunday by medical experts to be eligible to enter a phase 1 clinical trial, but only if certain conditions are met, the FDA said in a statement.
Chang Lien-cheng (張連成), the head of the Medicinal Products Division at the FDA, said the company must first look for 60 able-bodied and healthy individuals for the trial.
For safety reasons, the people chosen will have to undergo toxicity testing before the COVID-19 trial, which is expected to take place at National Taiwan University Hospital, Chang said.
The Ministry of Health and Welfare is still waiting on the company to provide additional technical data about the vaccine, and only after the data is received can the process begin, he said.
According to the health official, if things move forward as scheduled, the vaccine by Adimmune would likely be the first to enter a clinical trial in the country.
(By Chen Wei-ting and Ko Lin)
Enditem/ls
|
NEWSLETTER
|
| Join the GlobalSecurity.org mailing list |
|
|
|
